SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Illustration of a group of businessmen white-collar workers dismissed
Layoffs
Fractyl Goes All In on GLP-1 Off-Ramp Drug, Lays of 17% of Workforce
Fractyl Health is deprioritizing a type 2 diabetes trial in favor of a pivotal study of its endoscopy treatment Revita and parting with around 22 employees in an attempt to extend its runway into 2026.
January 31, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Composite contemporary collage statue of justice themis femida on the background of the target as the concept and idea of justice and law. High quality photo
Editorial
You Can’t Buy Us: Biotechs Turn to Courts to Fight Off Potential Buyers
Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO underscore the cutthroat nature of biopharma dealmaking.
January 31, 2025
 · 
3 min read
 · 
Annalee Armstrong
Profile view, and Mental Illness
Approvals
Axsome’s Migraine Medicine Clears FDA Bar
The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex’s non-opioid treatment Journavx.
January 31, 2025
 · 
2 min read
 · 
Tristan Manalac
Novartis head office building in Dorval, Quebec, Canada
Earnings
Novartis Eyes More Bolt-On Deals in 2025 as Q4 Earnings Easily Beat Consensus
Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.
January 31, 2025
 · 
2 min read
 · 
Tristan Manalac
Government
RFK Jr. Again Faces Scrutiny Over Vaccines on Day 2 of Confirmation Hearing
Senators on the Health, Education, Labor and Pensions committee were critical of Kennedy’s long history as an anti-vaccine campaigner.
January 31, 2025
 · 
2 min read
 · 
Tristan Manalac
A piggy bank crammed with $100 bills on a background of American cash
Venture capitalists
Blackstone Launches New $5B+ Fund for Life Sciences
Blackstone joins other big investors such as ARCH Venture Partners and Bain Capital Life Sciences in pumping billions of dollars into the industry.
January 31, 2025
 · 
2 min read
 · 
Tristan Manalac
Entrance to Vertex's office in Boston, Massachusetts
FDA
FDA Approves Vertex’s Journavx as First New Pain Drug in Decades
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum in the fledgling non-opioid pain space.
January 30, 2025
 · 
4 min read
 · 
Heather McKenzie
Pictured: Takeda sign at its office in Massachusetts
Business
Takeda Drops Epilepsy Drug, Names New CEO Amid Q3 Earnings
Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while responding positively to the announcement that Julie Kim will take the helm of the Japanese giant in 2026.
January 30, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Concept art for large layoffs showing a line of blocks a cliff
Layoffs
Cargo Halts CAR T Trial, Lays Off 50% of Workforce in Pipeline Reset
CAR T–focused biotech Cargo Therapeutics surprised and disappointed analysts when it announced that it would discontinue a mid-stage trial of its lead program, firi-cel.
January 30, 2025
 · 
2 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS